{"id":"intrathecal-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Chemical arachnoiditis"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection at injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is an administration route rather than a single drug entity; chemotherapy agents (commonly methotrexate, cytarabine, or hydrocortisone) are injected directly into the intrathecal space via lumbar puncture or ventricular reservoir. This approach achieves high local concentrations in the cerebrospinal fluid while minimizing systemic exposure, allowing treatment of CNS-penetrating cancers and prophylaxis of meningeal involvement in hematologic malignancies.","oneSentence":"Intrathecal chemotherapy delivers chemotherapeutic agents directly into the cerebrospinal fluid to treat central nervous system malignancies and prevent leptomeningeal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:49.310Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis and treatment of leptomeningeal disease in pediatric acute lymphoblastic leukemia"},{"name":"CNS involvement in pediatric lymphomas and other hematologic malignancies"},{"name":"Primary CNS tumors in pediatric patients"}]},"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT07471230","phase":"PHASE2","title":"Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism","status":"NOT_YET_RECRUITING","sponsor":"Biocells Medical","startDate":"2026-11-23","conditions":"Parkinsonism or Parkinson's Disease Nos, Parkinsonism in Diseases Classified Elsewhere","enrollment":120},{"nctId":"NCT06177067","phase":"PHASE1","title":"Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-04-19","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":24},{"nctId":"NCT05257941","phase":"PHASE1, PHASE2","title":"ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery","status":"TERMINATED","sponsor":"Indiana University","startDate":"2022-01-27","conditions":"Surgery","enrollment":116},{"nctId":"NCT07443514","phase":"NA","title":"Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2022-01-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07203742","phase":"NA","title":"The Effect of Mandala on Anxiety and Fear Levels in Children With Leukemia Before Intrathecal Chemotherapy Treatment","status":"RECRUITING","sponsor":"Ege University","startDate":"2025-09-29","conditions":"Acute Lymphoblastic Leukemia, Childhood Acute Leukemia, Acute Myeloblastic Leukaemia","enrollment":60},{"nctId":"NCT07404982","phase":"PHASE2","title":"Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-02","conditions":"Joint Replacement Surgery","enrollment":20},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT04994717","phase":"PHASE3","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-11-02","conditions":"Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","enrollment":304},{"nctId":"NCT07398599","phase":"NA","title":"Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-02-15","conditions":"Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07387926","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-26","conditions":"Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT05656248","phase":"PHASE2","title":"Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-01-17","conditions":"Myeloid Neoplasm","enrollment":25},{"nctId":"NCT06296745","phase":"PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-09-01","conditions":"Leptomeningeal Metastasis","enrollment":36},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT04898894","phase":"PHASE1","title":"Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-11-15","conditions":"Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage","enrollment":37},{"nctId":"NCT06620809","phase":"PHASE1","title":"The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-03-28","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":69},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT05809752","phase":"PHASE1","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-22","conditions":"Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer","enrollment":18},{"nctId":"NCT02870907","phase":"PHASE2","title":"Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2010-03-18","conditions":"Retinoblastoma","enrollment":195},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07304739","phase":"PHASE2","title":"Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-22","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT03378414","phase":"PHASE2","title":"Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia","status":"NOT_YET_RECRUITING","sponsor":"Sclnow Biotechnology Co., Ltd.","startDate":"2025-12-31","conditions":"Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3","enrollment":45},{"nctId":"NCT07263425","phase":"PHASE2","title":"Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-10-27","conditions":"Leptomeningeal Metastasis of HER2-positive Breast Cancer","enrollment":26},{"nctId":"NCT07258043","phase":"","title":"Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Hospital General de Mexico","startDate":"2025-07-23","conditions":"Acute Lymphobkastic Leukemia, Leukemia, Overall Survival","enrollment":45},{"nctId":"NCT07187427","phase":"NA","title":"Incidence of Pruritus Using Intrathecal Fentanyl Versus Epidural Fentanyl to Initiate Labour Analgesia.","status":"NOT_YET_RECRUITING","sponsor":"St. Justine's Hospital","startDate":"2026-01","conditions":"Pruritis, Hypotension Drug-Induced, Urinary Retention","enrollment":80},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":"HER2-negative Breast Cancer, Leptomeningeal Metastasis","enrollment":37},{"nctId":"NCT05146739","phase":"PHASE1","title":"Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-10","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome","enrollment":8},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT06031259","phase":"PHASE2, PHASE3","title":"Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2024-03-05","conditions":"Hunter Syndrome","enrollment":6},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT05519579","phase":"PHASE2","title":"Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2023-06-30","conditions":"Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT06376162","phase":"PHASE1","title":"Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2025-03-18","conditions":"Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia","enrollment":20},{"nctId":"NCT04606264","phase":"PHASE3","title":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","status":"COMPLETED","sponsor":"Jennifer Holder-Murray","startDate":"2023-05-15","conditions":"Perioperative Optimization","enrollment":2977},{"nctId":"NCT01760226","phase":"EARLY_PHASE1","title":"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":"Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma","enrollment":4},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT06462222","phase":"PHASE1, PHASE2","title":"Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2024-06-30","conditions":"Leptomeningeal Metastasis","enrollment":45},{"nctId":"NCT06462092","phase":"PHASE1, PHASE2","title":"Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2026-01-01","conditions":"Leptomeningeal Metastases","enrollment":34},{"nctId":"NCT06304441","phase":"NA","title":"Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2024-04-18","conditions":"Leptomeningeal Metastasis","enrollment":100},{"nctId":"NCT07193654","phase":"PHASE2","title":"Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Glioblastoma (GBM)","enrollment":38},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT05745714","phase":"PHASE1, PHASE2","title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07175415","phase":"PHASE1, PHASE2","title":"HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2026-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory","enrollment":42},{"nctId":"NCT05658640","phase":"PHASE1, PHASE2","title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-11-14","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT05751044","phase":"PHASE1, PHASE2","title":"HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-10-01","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":26},{"nctId":"NCT07168980","phase":"PHASE2, PHASE3","title":"Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2025-07-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT07153614","phase":"NA","title":"Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2025-02-03","conditions":"Perioperative Opioid Sparing Techniques","enrollment":200},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT05993273","phase":"NA","title":"Pain Control After VATS Anatomical Pulmonary Resections","status":"COMPLETED","sponsor":"University Hospital Padova","startDate":"2023-04-05","conditions":"Lung Cancer, Pain, Postoperative, Thoracic Neoplasms","enrollment":75},{"nctId":"NCT07092202","phase":"PHASE4","title":"Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-04-15","conditions":"Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy","enrollment":40},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT06516679","phase":"PHASE2","title":"Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-12-11","conditions":"Leukemia, Lymphoid","enrollment":40},{"nctId":"NCT05521087","phase":"PHASE1","title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-26","conditions":"Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT05827549","phase":"PHASE2","title":"Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Ho Joon Im","startDate":"2024-04-04","conditions":"Acute Lymphoid Leukemia","enrollment":90},{"nctId":"NCT02303821","phase":"PHASE1","title":"Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-16","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":141},{"nctId":"NCT06034561","phase":"PHASE2","title":"Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2024-04-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission","enrollment":50},{"nctId":"NCT06971406","phase":"PHASE2","title":"High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Qiming Wang","startDate":"2025-05-15","conditions":"Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases","enrollment":100},{"nctId":"NCT05289908","phase":"PHASE1, PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2022-02-21","conditions":"Leptomeningeal Metastases","enrollment":34},{"nctId":"NCT03475121","phase":"PHASE3","title":"Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma","status":"COMPLETED","sponsor":"Hospital JP Garrahan","startDate":"2018-01-01","conditions":"Unilateral Retinoblastoma","enrollment":84},{"nctId":"NCT03792256","phase":"PHASE1","title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2019-04-11","conditions":"Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma","enrollment":12},{"nctId":"NCT06424587","phase":"NA","title":"The Effect of Music Intervention on Anxiety, Fear, and Pain in Pediatric Patients Receiving Intrathecal Chemotherapy","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2023-01-01","conditions":"Nurse's Role","enrollment":50},{"nctId":"NCT00619879","phase":"","title":"Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2007-03-26","conditions":"Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":81},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":"Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT06643000","phase":"NA","title":"Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-12-20","conditions":"Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation","enrollment":60},{"nctId":"NCT06861218","phase":"PHASE2","title":"Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-04","conditions":"Leptomeningeal Metastases","enrollment":42},{"nctId":"NCT04903678","phase":"NA","title":"Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-05-01","conditions":"Retinoblastoma, Extraocular","enrollment":18},{"nctId":"NCT06812871","phase":"PHASE2","title":"High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":30},{"nctId":"NCT06775431","phase":"PHASE3","title":"Comparing Prophylactic Intravenous Pethidine and Intrathecal Pethidine in Preventing Post Spinal Shivering in Caesarean Section","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-12-10","conditions":"Pregnant Women","enrollment":86},{"nctId":"NCT06153602","phase":"NA","title":"Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-07","conditions":"Transurethral Resection of Prostate","enrollment":80},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT00801216","phase":"PHASE2","title":"High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement","status":"COMPLETED","sponsor":"Andrés José Maria Ferreri","startDate":"2007-01","conditions":"B-cell Lymphomas","enrollment":40},{"nctId":"NCT06722638","phase":"NA","title":"Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-08-30","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":40},{"nctId":"NCT05257018","phase":"PHASE2","title":"R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-02-26","conditions":"Diffuse Large B-cell Lymphoma","enrollment":83},{"nctId":"NCT06655103","phase":"NA","title":"The Effect of the Educational Movie Shown to Pediatric Patients Receiving Intrathecal Chemotherapy Treatment on Pre-Procedure Fear and Post-Procedure Pain in Children","status":"NOT_YET_RECRUITING","sponsor":"Ege University","startDate":"2024-11-30","conditions":"Injections, Spinal, Child, Only, Virtual Reality","enrollment":99},{"nctId":"NCT06649422","phase":"","title":"Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Shandong University","startDate":"2024-11-01","conditions":"Leukemia, Lymphocytic, Acute, Adult","enrollment":36},{"nctId":"NCT06543992","phase":"PHASE2","title":"Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-07-13","conditions":"Leptomeningeal Metastasis of Breast Cancer","enrollment":22},{"nctId":"NCT05740449","phase":"PHASE1, PHASE2","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"WITHDRAWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":""},{"nctId":"NCT06431685","phase":"PHASE1","title":"Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-25","conditions":"NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06346977","phase":"","title":"Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-04-01","conditions":"Diagnosis","enrollment":60},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT01186328","phase":"PHASE1","title":"EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08-24","conditions":"Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell","enrollment":6},{"nctId":"NCT06190457","phase":"","title":"Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2015-09-30","conditions":"Lymphoma, Non-Hodgkin, Child, Only","enrollment":16},{"nctId":"NCT06181526","phase":"PHASE1","title":"Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-12-15","conditions":"Amyotrophic Lateral Sclerosis","enrollment":24},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Lymphoma, Lymphoblastic","enrollment":50},{"nctId":"NCT05877690","phase":"NA","title":"Selective Spinal Anaesthesia With Hyperbaric Prilocain With 2%Provides Better Perioperative Hemodynamic Stability for Patients With Peripheral Vascular Disease and Cardiac Dysfunction in Lower Limb Surgery","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-10","conditions":"Hemodynamic Stability","enrollment":80},{"nctId":"NCT04006561","phase":"","title":"Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-03-01","conditions":"Primary CNS Lymphoma, Brain Lymphoma","enrollment":36},{"nctId":"NCT05810350","phase":"PHASE2","title":"Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles","status":"UNKNOWN","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2023-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03688451","phase":"PHASE2","title":"Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Tahir Latif","startDate":"2018-10-29","conditions":"Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03194932","phase":"PHASE1","title":"Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-07-11","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT03349281","phase":"PHASE1","title":"Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL","status":"COMPLETED","sponsor":"Julio Barredo, MD","startDate":"2019-03-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":6},{"nctId":"NCT05566405","phase":"NA","title":"The Effects of Method of Anaesthesia on the Safety and Effectiveness of Radical Retropubic Prostatectomy","status":"COMPLETED","sponsor":"Sismanoglio General Hospital","startDate":"2020-07-27","conditions":"Prostatic Neoplasm","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DRUG INTERACTION"},{"count":4,"reaction":"MUCOSAL INFLAMMATION"},{"count":2,"reaction":"DRUG TOXICITY"},{"count":1,"reaction":"BLOOD LACTATE DEHYDROGENASE ABNORMAL"},{"count":1,"reaction":"BLOOD LACTATE DEHYDROGENASE INCREASED"},{"count":1,"reaction":"BLOOD PH INCREASED"},{"count":1,"reaction":"CANDIDA OSTEOMYELITIS"},{"count":1,"reaction":"DRUG CLEARANCE DECREASED"},{"count":1,"reaction":"DRUG LEVEL INCREASED"},{"count":1,"reaction":"INHIBITORY DRUG INTERACTION"}],"_approvalHistory":[],"publicationCount":1391,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cytosine Arabinoside","Ara-C","Cytosar®","NSC #63878 (102004)"],"phase":"marketed","status":"active","brandName":"intrathecal chemotherapy","genericName":"intrathecal chemotherapy","companyName":"Princess Maxima Center for Pediatric Oncology","companyId":"princess-maxima-center-for-pediatric-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intrathecal chemotherapy delivers chemotherapeutic agents directly into the cerebrospinal fluid to treat central nervous system malignancies and prevent leptomeningeal disease. Used for Prophylaxis and treatment of leptomeningeal disease in pediatric acute lymphoblastic leukemia, CNS involvement in pediatric lymphomas and other hematologic malignancies, Primary CNS tumors in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}